Novel RSV prevention vaccine antigen with improved stability of prefusion f (pre-f)

A recombinant RSV F protein with specific mutations stabilizes the pre-fusion form, addressing the ineffectiveness of existing vaccines against the B strain and reducing the economic burden by enhancing vaccine efficacy.

WO2026235483A1PCT designated stage Publication Date: 2026-11-12KOREA NAT INST OF HEALTH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2026/096646
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2026-05-04
Filing Date
2026-05-07
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing RSV vaccines based on the A2 strain sequence are ineffective against the domestically prevalent B strain, leading to inconsistent preventive efficacy and high economic burden due to the need for annual vaccinations, and they fail to maintain the stable pre-fusion F form, reducing antigenicity.

Method used

A recombinant RSV F protein with specific amino acid mutations (S155C, S290C, S190F, V207L, R106N, R108N, R135Q, R136Q, D486N, K226Y) is developed to stabilize the pre-fusion form, enhancing its stability and antigenicity, and is used in a vaccine composition.

Benefits of technology

The recombinant RSV F protein maintains a stable pre-fusion form, improving vaccine efficacy and reducing the need for frequent vaccinations, offering a cost-effective solution for RSV prevention.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2026096646_12112026_PF_FP_ABST
    Figure KR2026096646_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a recombinant respiratory syncytial virus (RSV) F protein with improved stability of a pre-F form, and a vaccine composition for the prevention or treatment of RSV infection, comprising same. The recombinant RSV F protein of the present invention introduces an independent amino acid mutation on the basis of the amino acid sequences of a domestic epidemic RSV B strain, thereby enhancing pre-F protein stability to improve vaccine persistence in the human body, and thus may be widely used as a RSV infection prevention vaccine in various formulations such as a subunit vaccine, mRNA vaccine, VLP vaccine, and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Novel RSV vaccine antigen with enhanced pre-fusion F(PRE F) stability

[0001] The present invention relates to a recombinant respiratory syncytial virus (RSV) F protein with improved stability in the Pre F form and a vaccine composition for the prevention or treatment of RSV infection containing the same.

[0002]

[0003] Respiratory syncytial virus (RSV) causes respiratory infections in infants and young children under the age of 5 and adults, with approximately 88,000 cases of acute respiratory infection occurring annually in Korea. In particular, it is known as the most common cause of pneumonia in infants under the age of 1.

[0004] In the late 1960s, an inactivated RSV vaccine treated with formalin was developed to prevent RSV infections; however, immunological side effects were identified, such as the denaturation of antigen proteins by formalin treatment leading to the abnormal activation of helper T cells (Th2) and lung damage caused by neutrophil concentration. Subsequently, continuous research and development for RSV vaccines identified the structure of the RSV F protein and the resulting differences in antigenicity, marking a major turning point in the development of RSV vaccines utilizing pre-fusion F (Pre-F) antigens. The RSV F protein enables viral entry by fusing RSV with the host cell membrane and mediates the fusion of infected cells to form a characteristic syncytium. The RSV F protein takes on different forms before and after fusion with host cells, and antibodies that bind better to the Pre-F form of the protein are known to be more efficient in neutralizing RSV and preventing infection.

[0005] Although global pharmaceutical companies abroad are developing RSV preventive vaccines based on the Pre F antigen, vaccines approved overseas carry a significant financial burden due to high vaccination costs. In particular, they show a sharp decline in preventive efficacy in the second year compared to the first, which is expected to increase the economic burden if annual vaccination becomes necessary. Furthermore, since these vaccines were developed based on the sequence of the standard RSV-A virus strain A2 (U.S. Patent No. 11,034,731), they differ from the prevalent RSV-A (ON.1 strain) in Asia, including Korea, in the amino acid sequence of the F protein, making it impossible to predict their preventive efficacy against RSV-B (BA strain). According to long-term surveillance data in Korea, over the past decade, RSV has shown a pattern where types A and B alternately become dominant seasonally, centered around the ON.1 lineage (RSV A) and the BA lineage (RSV B). Given these epidemic characteristics, it is difficult to secure consistent preventive efficacy every season with monocost vaccines optimized for a specific single antigen type, and it is expected that it will be difficult to narrow the antigenic gap with the domestically circulating strain in the medium to long term using only a vaccine strategy relying on a single A2 strain-based F antigen.

[0006] Accordingly, the inventors conducted research to develop an effective and economical RSV preventive vaccine antigen for domestic populations. As a result, they secured an antigen that maintains a stable Pre-F form based on the amino acid sequence of RSV-B, a domestically prevalent strain, and completed the present invention by confirming its expression characteristics and antigenicity.

[0007] The present application electronically submits a sequence list in XML format conforming to WIPO ST.26, said sequence list constituting part of the present specification and the whole thereof is incorporated by reference into the present specification.

[0008]

[0009] One objective of the present invention is to provide a recombinant RSV F protein with increased stability in the Pre F form by introducing an amino acid mutation into the F protein of a domestically prevalent wild-type respiratory syncytial virus (RSV) strain.

[0010] Another objective of the present invention is to provide a vaccine composition for the prevention or treatment of RSV infection comprising the recombinant RSV F protein.

[0011]

[0012] Specifically, the details are as follows. Meanwhile, each description and embodiment disclosed in the present invention may be applied to each other description and embodiment. That is, all combinations of the various elements disclosed in the present invention fall within the scope of the present invention. Furthermore, the scope of the present invention should not be considered limited by the specific descriptions provided below.

[0013]

[0014] One aspect of the present invention relates to a recombinant RSV F protein in which S155C, S290C, S190F, V207L, R106N, R108N, R135Q, R136Q, D486N, and K226Y amino acid substitutions are introduced into the wild-type respiratory syncytial virus (RSV) F protein.

[0015] The "Respiratory syncytial virus (hereinafter RSV)" of the present invention is a typical pneumovirus belonging to the family Pneumoviridae, and includes human RSV, bovine RSV, and rodent pneumonia virus. The RSV of the present invention may refer to human RSV, but is not limited thereto. Human RSV is classified into two subgroups, RSV-A and RSV-B, based on antigenicity, and genotypes such as CB-A and ON1 have been identified in RSV-A strains, while genotypes such as BA1-12 and BA.4 have been identified in RSV-B strains (Scientific Reports 7:5501, 2017). The genome of RSV consists of a genome approximately 15.2 kb in length and contains 10 genes encoding a total of 11 proteins. Of the 11 proteins, 3 are non-structural proteins (NS1, NS2, M2-2) and 8 are structural proteins; among the structural proteins, the adhesion glycoprotein G protein targets the airway ciliated cells of host cells to mediate the attachment of RSV. Another important structural protein, the fusion glycoprotein F (fusion) protein, mediates viral entry and syncytium formation, and divides into F1 and F2, which form a heterodimer trimer. The RSV F protein on the surface of the virion exists in a metastable pre-fusion (Pre-F) form that naturally transitions into a stable post-fusion form during membrane fusion. In other words, the RSV F protein has different forms before and after fusion with the host cell, and the presence and extent of exposure to the six core antigen sites (Ø-V) to which neutralizing antibodies react—which play the most critical role in the immune response to RSV—depend on the pre- and post-fusion forms of the F protein. In the pre-F form, the protein exists in a trimer form and contains a major antigen site Ø, which becomes a major target for neutralizing antibodies in the body. In the present invention, "Pre F form" or "Pre F protein" may be used interchangeably.

[0016] The terms "protein" or "polypeptide" in the present invention refer to a collection of amino acids generated by encoding a specific nucleic acid, meaning a unit composed of two or more amino acids. In the technical field of the present invention, the terms "protein" or "polypeptide" may be understood to mean "antigen" or "immunogen."

[0017] The terms "wild-type protein" or "wild-type sequence" of the present invention refer to a naturally occurring protein or sequence that has not been artificially modified by selective mutation. The wild-type RSV F protein of the present invention differs from the F protein sequence of the standard strain A2 of the RSV-A virus and refers to the F protein of RSV strains prevalent in Korea and Asia, particularly RSV B strains. The wild-type RSV F protein may consist of the amino acid sequence of SEQ ID NO. 1, but is not limited thereto.

[0018] The terms "mutation" or "amino acid mutation" in the present invention refer to the deletion, addition, or substitution of an amino acid residue in the amino acid sequence of a protein or polypeptide when compared to the amino acid sequence of a reference protein or polypeptide. In the present invention, the substitution of an amino acid at a specific position in a protein sequence is referred to using the notation "(amino acid residue in wild-type protein)(amino acid position)(amino acid residue in modified protein)". For example, the notation "S155C" refers to the substitution of a serine (S) residue at position 155 of the amino acid sequence of a reference protein with a cysteine ​​(C) residue.

[0019] The present invention aims to provide a recombinant RSV F protein comprising an amino acid sequence that is mutated, mutated, or modified compared to a wild-type RSV F protein. Specifically, the invention provides a novel recombinant RSV F protein obtained through mutation or modification of one or more amino acid sequences of a wild-type RSV F protein, and the use thereof as an immunogen against RSV.

[0020] The recombinant RSV F protein of the present invention is a wild-type RSV F protein from which the transmembrane domain has been excluded, into which a) a DS-Cav1 mutation (DC); b) a furin cleavage site mutation (FM); and c) a trimer formation enhancement (TE) modification have been introduced. It is known that RSV F protein undergoes cleavage at the furin cleavage site during the process of entering host cells, converting into a post-fusion form, and that major neutralizing epitopes are lost during this process, resulting in a significant decrease in antigenicity. Therefore, to utilize it as a vaccine antigen, it is essential to stably maintain the F protein in a pre-fusion form, and to this end, structural stabilization was induced by applying mutation and cleavage strategies to the furin cleavage site. Specifically, the recombinant RSV F protein is a wild-type RSV B F protein into which S155C, S290C, S190F, V207L, R106N, R108N, R135Q, R136Q, D486N, and K226Y amino acid substitutions have been introduced. More specifically, the recombinant RSV F protein may consist of the amino acid sequence of SEQ ID NO. 5, but is not limited thereto. The recombinant RSV F protein is characterized by improved stability compared to the F protein of wild-type RSV B.

[0021] In the present invention, 45 novel recombinant RSV F proteins were produced by additionally introducing combinations of point mutations based on SEQ ID NO. 5 to structurally stabilize them, and among the 45 RSV B Pre F antigen candidates, a relatively superior antigen candidate was selected by comprehensively considering the ability to maintain the Pre F structure and antigenicity.

[0022] The recombinant RSV F protein of the present invention may further include one or more amino acid substitutions selected from the group consisting of N228K, E232N, L203I, and S215P. Specifically, the recombinant RSV F protein may be composed of any one of the amino acid sequences of SEQ ID NOs 6 to 20, and more specifically, the recombinant RSV F protein may be composed of the amino acid sequence of SEQ ID NO. 11 or SEQ ID NO. 14.

[0023] The recombinant RSV F protein of the present invention may further include an amino acid substitution of N67I, N67F, or N67W. Specifically, the recombinant RSV F protein may be composed of any one of the amino acid sequences of SEQ ID NOs 21 to 23, and more specifically, the recombinant RSV F protein may be composed of the amino acid sequence of SEQ ID NO. 21 or SEQ ID NO. 22.

[0024] The recombinant RSV F protein of the present invention may further include one or more amino acid substitutions selected from the group consisting of N428Y, V185Y, and V220Y. Specifically, the recombinant RSV F protein may be composed of any one of the amino acid sequences of SEQ ID NOs 24 to 30, and more specifically, the recombinant RSV F protein may be composed of the amino acid sequence of SEQ ID NO. 27 or SEQ ID NO. 30.

[0025] The recombinant RSV F protein of the present invention may further include one or more amino acid substitutions selected from the group consisting of Q98C, Q361C, N183C, and A149C. Specifically, the recombinant RSV F protein may be composed of any one of the amino acid sequences of SEQ ID NOs 31 to 45, and more specifically, the recombinant RSV F protein may be composed of the amino acid sequence of SEQ ID NO. 31 or SEQ ID NO. 32.

[0026] The recombinant RSV F protein of the present invention may further include amino acid substitutions of I79M, P101S, P101Q, I152V, or I152M. Specifically, the recombinant RSV F protein may be composed of any one of the amino acid sequences of SEQ ID NOs 46 to 50, and more specifically, the recombinant RSV F protein may be composed of the amino acid sequence of SEQ ID NO. 46 or SEQ ID NO. 49.

[0027]

[0028] Another aspect of the present invention is to provide a polynucleotide encoding the recombinant RSV F protein. The term "polynucleotide" in the art of the present invention is understood to mean "nucleic acid." Polynucleotide sequences may be cloned using conventional molecular biology techniques or newly generated by DNA synthesis, which may be performed using conventional procedures by a service provider engaged in the field of DNA synthesis and / or molecular cloning. Polynucleotide molecules of the present invention are codon-optimized for expression in mammalian cells, preferably human cells. Methods of codon-optimization are known in the art of the present invention, and a sequence is considered codon-optimized if, compared to a wild-type sequence, at least one non-preferential codon is replaced by a more preferential codon. It will be understood by those skilled in the art that, as a result of degeneracy of the genetic code, many different polynucleotide and nucleic acid molecules may encode the same polypeptide. It will also be understood that those skilled in the art can, using routine techniques, make nucleotide substitutions that do not affect the polypeptide sequence encoded by the nucleic acid molecule to reflect the codon usage of any particular host organism in which the polypeptide is expressed. Therefore, unless otherwise specified, "polynucleotide sequences encoding an amino acid sequence" include all nucleotide sequences that are mutually axial and that encode the same amino acid sequence. Polynucleotide sequences encoding RNA and proteins may or may not contain introns.

[0029]

[0030] Another aspect of the present invention is to provide an expression vector comprising the polynucleotide. The polynucleotide molecule may be part of the vector. The expression vector of the present invention can be easily manipulated by methods well known to those skilled in the art and may be designed to be replicable in prokaryotic and / or eukaryotic cells. Alternatively, the expression vector may be designed not to be replicable. The expression vector of the present invention may be, for example, an adenovector comprising Ad26 or AD35, an alphavirus, a paramyxovirus, a vaccinia virus, a herpes virus, or a retrovirus vector, but is not limited thereto. Those skilled in the art may select a suitable expression vector and insert the polynucleotide sequence of the present invention in a functional manner.

[0031]

[0032] Another aspect of the present invention provides a transformed host cell into which the expression vector has been introduced. Eukaryotic host cells are yeast, insect, algae, plant, Caenorhabditis elegans (or nematodes), and mammalian host cells. Non-limiting examples of insect cells are, for example, Spodopterafrugiperda (SF) cells such as SF9 and SF21, Trichoplusia ni cells such as Hi-Five cells, and Drosophila S2 cells. Examples of fungal (including yeast) host cells are species of Candida including S. cerevisiae, Kluyveromyces lactis (K. lactis), C. albicans and C. glabrata, Aspergillus nidulans, Schizosaccharomyces pombe (S. pombe), Pichia pastoris, and Yarrowia lipolytica. Examples of mammalian cells include COS cells, baby hamster kidney cells, mouse L cells, LNCaP cells, Chinese hamster ovary (CHO) cells, human embryonic kidney (HEK) cells, African green monkey cells, CV1 cells, HeLa cells, MDCK cells, Vero, and Hep-2 cells. Xenopus laevis oocytes or other cells from amphibian sources may also be used. Prokaryotic host cells include, for example, bacterial cells such as Escherichia coli (E. coli, B. subtilis), Salmonella typhi, and mycobacteria. The host cells of the present invention may be in vitro cells, isolated host cells, or host cells isolated from humans, but are not limited thereto.

[0033]

[0034] Another aspect of the present invention is to provide a virus-like particle comprising the recombinant RSV F protein. The "virus-like particle (VLP)" of the present invention refers to a non-replicating or non-infectious viral particle, or to a non-replicating or non-infectious structure resembling a viral particle, preferably a viral capsid. The term "non-replicating" means that the genome contained by the virus-like particle cannot be replicated, and "non-infectious" means that it cannot enter a host cell. The virus-like particle of the present invention may contain nucleic acids different from its genome, and recombinant virus-like particles typically contain host cell-induced RNA.

[0035] The virus-like particle of the present invention may additionally include an influenza protein, specifically an influenza M1 protein (matrix protein 1). The influenza M1 protein of the present invention is a structural protein of the influenza virus and refers to a matrix protein that forms a coat inside the lipid layer, which is the outer shell of the influenza virus. The virus-like particle of the present invention may include the influenza M1 protein as a structural protein, but is not limited thereto. The influenza M1 protein of the present invention may be composed of the amino acid sequence of SEQ ID NO. 51.

[0036]

[0037] Another aspect of the present invention is to provide a vaccine composition for the prevention or treatment of RSV infection comprising the recombinant RSV F protein, polynucleotide, expression vector, host cell, or virus-like particle.

[0038] RSV causes RSV infection in all age groups and is transmitted through direct transmission via respiratory droplets or indirect transmission such as contact with secretions. In particular, it is prevalent in Korea from October to March of the following year. As a major cause of hospitalization for infants and young children under the age of 5, the number of deaths among infants due to bronchiolitis and pneumonia resulting from RSV lower respiratory tract infections reaches 150,000 annually, and approximately 93% or more of all infected individuals in the country are under the age of 6. While healthy adults have a lower fatality rate and lower risk of developing severe disease compared to infants and young children, symptoms such as coughing, increased sputum production, and shortness of breath develop over several days; in immunocompromised individuals, the elderly aged 65 or older, or those with a history of underlying heart or lung diseases, it can lead to severe illness.

[0039] The term "prevention" of the present invention refers to any act of suppressing or delaying a disease through the administration or treatment of a composition containing the recombinant RSV F protein of the present invention as an active ingredient or immunogen. The term "treatment" of the present invention refers to any act of improving or beneficially altering the symptoms of a disease through the administration or treatment of a composition containing the recombinant RSV F protein of the present invention as an active ingredient or immunogen.

[0040] The term "vaccine" in the present invention refers to a pharmaceutical composition comprising an immunogen capable of inducing a prophylactic or therapeutic immune response in a subject. Generally, vaccines induce an antigen-specific immune response against an antigen of a pathogen, such as a viral pathogen. The vaccine of the present invention may be in the form of a recombinant protein vaccine, a subunit vaccine, or a Virus-like Particles (VLP) vaccine, but is not limited thereto.

[0041] In the present invention, neutralizing antibody titers and cell-mediated immune responses were confirmed using a mouse (6-week-old BALB / c) model to evaluate the immunogenicity of the vaccine candidate. The vaccine candidate was administered by intramuscular injection at a dose of 10 µg per mouse. Vaccination was performed using a two-dose boosting method, where a second dose of the vaccine candidate at the same concentration was administered on day 14 after the first dose. Blood collection for serum was performed twice: once on day 14 after the first vaccination and twice on day 14 after the second vaccination. The isolated serum was inactivated at 56°C for 30 minutes, and then the neutralizing antibody titers against the domestically prevalent respiratory syncytial virus were measured using the FRNT (Focus Reduction Neutralization Test) method. Cell-mediated immune response was measured by extracting the spleen on day 14 of vaccination and stimulating secreted interferon gamma with a commercial RSV F peptide pool using the ELISPOT assay. As a result, it was confirmed that the immunogenicity of the vaccine candidate according to the present invention is excellent.

[0042]

[0043] Another aspect of the present invention provides a method for preventing or treating RSV infection, comprising the step of administering a composition containing the recombinant RSV F protein to a subject. The composition of the present invention can induce substantial immunity in a subject (e.g., a human). The composition may be administered with or without the administration of an adjuvant. The effective amount administered to the subject is sufficient to elicit an immune response to the RSV antigen, e.g., the RSV F protein, in the subject. Subjects that may be selected for treatment include subjects at risk of developing RSV infection due to exposure to or potential exposure to RSV. The administration of the composition provided in the present invention may be performed using standard administration routes, e.g., intradermal, intramuscular, subcutaneous, transdermal, mucosal, or oral administration, but is not limited thereto.

[0044]

[0045] The recombinant RSV F protein of the present invention introduces unique amino acid mutations based on the amino acid sequence of the domestically prevalent RSV B strain, thereby enhancing the stability of the pre-F protein and improving the persistence of the vaccine in the body; thus, it can be widely utilized as a vaccine in various formulations, such as subunits, mRNA, and VLPs, for the prevention of RSV infection.

[0046]

[0047] Figure 1 is a schematic diagram of the introduction of a selective variant to derive recombinant RSV F protein antigen candidates.

[0048] [Correction pursuant to Rule 91 07.07.2026] Figures 2(A) to (H) show the results of comparing the expression levels of Pre F proteins of 45 antigen candidates and 5 control groups for RSV B.

[0049] Figure 3 shows the results of immunofluorescence staining for localization after RSV F protein expression.

[0050] Figure 4 shows the results of flow cytometry analysis for 15 types included in RSV B Pre F antigen candidate group #1, where Figure 4(A) is the result for Nirsevimab antibody and Figure 4(B) is the result for Motavizumab antibody.

[0051] Figure 5 shows the results of flow cytometry analysis for three types included in RSV B Pre F antigen candidate group #2, where Figure 5(A) is the result for Nirsevimab antibody and Figure 5(B) is the result for Motavizumab antibody.

[0052] Figure 6 shows the results of flow cytometry analysis for 7 types included in RSV B Pre F antigen candidate group #3, where Figure 6(A) is the result for Nirsevimab antibody and Figure 6(B) is the result for Motavizumab antibody.

[0053] Figure 7 shows the results of flow cytometry analysis for 15 types included in RSV B Pre F antigen candidate group #4, where Figure 7(A) is the result for Nirsevimab antibody and Figure 7(B) is the result for Motavizumab antibody.

[0054] Figure 8 shows the results of flow cytometry analysis for five types included in the RSV B Pre F antigen candidate group #5, where Figure 8(A) is the result for Nirsevimab antibody and Figure 8(B) is the result for Motavizumab antibody.

[0055] Figures 9(A) to (E) show the results of re-verification of 10 primary selection candidates for RSV B Pre F antigens.

[0056] Figure 10 shows the results of the selection of the third antigen candidate group in Pre F antigen candidate group #1 of RSV B, where Figure 10(A) is the Nirsevimab MFI / Motavizumab MFI value, Figures 10(B) and (C) are the results for the Nirsevimab antibody, and Figures 10(D) and (E) are the results for the Motavizumab antibody.

[0057] Figure 11 shows the results of the selection of the third antigen candidate group in the Pre F antigen candidate group #2 of RSV B, where Figure 11(A) is the Nirsevimab MFI / Motavizumab MFI value, Figures 11(B) and (C) are the results for the Nirsevimab antibody, and Figures 11(D) and (E) are the results for the Motavizumab antibody.

[0058] Figure 12 shows the results of the selection of the third antigen candidate group in the Pre F antigen candidate group #3 of RSV B, where Figure 12(A) is the Nirsevimab MFI / Motavizumab MFI value, Figures 12(B) and (C) are the results for the Nirsevimab antibody, and Figures 12(D) and (E) are the results for the Motavizumab antibody.

[0059] Figure 13 shows the results of the selection of the third antigen candidate group in Pre F antigen candidate group #4 of RSV B, where Figure 13(A) is the Nirsevimab MFI / Motavizumab MFI value, Figures 13(B) and (C) are the results for the Nirsevimab antibody, and Figures 13(D) and (E) are the results for the Motavizumab antibody.

[0060] Figure 14 shows the results of the selection of the third antigen candidate group in Pre F antigen candidate group #5 of RSV B, where Figure 14(A) is the Nirsevimab MFI / Motavizumab MFI value, Figures 14(B) and (C) are the results for the Nirsevimab antibody, and Figures 14(D) and (E) are the results for the Motavizumab antibody.

[0061] Figure 15 shows the results of verifying the usefulness of the Pre F selected antigen of RSV B.

[0062]

[0063] Hereinafter, the present invention will be described in detail based on examples. However, the following examples are merely for illustrating the present invention and are not limited to the spirit or scope of the present invention.

[0064]

[0065] Example 1. Production of antigen candidates based on the sequence of domestically circulating Respiratory Syncytial Virus (RSV)

[0066] To derive a unique RSV Pre F antigen candidate, recombinant RSV B Pre F proteins were produced by introducing point mutations based on the F protein sequence (WT, SEQ ID NO. 1) of a domestically prevalent RSV B strain. Specifically, a control group was designed including the following modifications.

[0067] a) DS-Cav1 mutation (DC)

[0068] b) Purine cleavage variant (FM)

[0069] c) Enhancement of trimer formation (TE)

[0070]

[0071]

[0072]

[0073] Furthermore, 45 additional novel antigen candidates were derived by selectively introducing combinations of point mutations based on the above sequence number 5.

[0074]

[0075] Sequence No. Group Antigen Candidate Addition Variant 6#1#1-1N228K 7#1-2E232N 8#1-3L203I 9#1-4S215P10#1-5N228K, E232N 11#1-6N228K, L203I 12#1-7N228K, S215P13#1-8E232N, L203I 14#1-9E232N, S215P15#1-10L203I, S215P16#1-11N228K, E232N, L203I 17#1-12N228K, E232N, S215P18#1-13N228K, L203I, S215P19#1-14E232N, L203I, S215P20#1-15N228K, E232N, L203I, S215P21#2#2-1N67I22#2-2N67F23#2-3N67W24#3#3-1N428Y25#3-2V185Y26#3-3V220Y27#3-4N428Y, V185Y28#3-5N428Y, V220Y29#3-6V185Y, V220Y30#3-7N428Y, V185Y, V220Y31#4#4-1Q98C32#4-2Q361C33#4-3N183C34#4-4A149C35#4-5Q98C, Q361C36#4-6Q98C, N183C37#4-7Q98C, A149C38#4-8Q361C, N183C39#4-9Q361C, A149C40#4-10N183C, A149C41#4-11Q98C, Q361C, N183C42#4-12Q98C, Q361C, A149C43#4-13Q98C, N183C, A149C44#4-14Q361C, N183C, A149C45#4-15Q98C, Q361C, N183C, A149C46#5#5-1I79M47#5-2P101S48#5-3P101Q49#5-4I152V50#5-5I152M

[0076]

[0077] The novel antigen candidates of sequence numbers 1 to 50, which were finally derived, were subjected to codon optimization to be expressed in insect cells, and then sequence synthesis was carried out by commissioning Cosmojintech Co., Ltd., a company specializing in gene sequence synthesis.

[0078]

[0079] Example 2: Construction of a recombinant baculovirus (rAc MNPV) expressing a novel RSV Pre F protein

[0080] To construct a recombinant baculovirus (recombinantautographa californicamultiple nucleopolyhedrovirus (rAcMNPV)) into which the novel antigen candidate sequences produced in Example 1 were introduced, the gene sequences of recombinant RSV BF proteins of SEQ ID NOs. 1 to 50, including five control types, were cloned into the baculovirus transfection vector pOET1 (OXFORD EXPRESSION TECHNOLOGIES LTD, Oxford, UK). Then, together with the AcMNPV DNA, co-transfection was performed on insect cell line Sf9 (Spodoptera frugiperda9, Thermo Fisher Scientific, MA, USA) cells using the reagent BaculoFECTIN II (OXFORD EXPRESSION TECHNOLOGIES LTD, Oxford, UK). Starting three days after co-transfection, the production of recombinant baculovirus was confirmed by phase-contrast microscopy, and the infected lesions of the recombinant baculovirus were plaque-purified and used in the experiment.

[0081]

[0082] Example 3: Expression Analysis of Novel RSV Pre F Protein

[0083] To confirm the expression of the novel RSV F protein in insect cells, each recombinant baculovirus prepared in Example 2 above was placed in a 12-well plate at a rate of 5×10⁻⁶ 5 Sf9 cells dispensed at cells / ml were collected on the 3rd day after inoculation (infection) at 1 MOI (multiplicity of infection).

[0084] Subsequently, for Western blot analysis using a monoclonal antibody specific to RSV F (2F7, Abcam, Cambridge, UK), the SDS-PAGE gel was transferred to a 0.2 μm PVDF membrane (Bio-rad, CA, USA), and EveryBlot Blocking Buffer (Bio-rad, CA, USA) was applied for 30 minutes for blocking. Then, the anti-respiratory syncytial virus antibody 2F7 (abcam, Cambridge, UK), which is specific to RSV F, was diluted in TBS-T (20 mM Tris, 150 mM NaCl, 0.1% Tween 20, pH 7.4) and treated for 1 hour, followed by washing three times for 15 minutes each with TBS-T. The secondary antibody (anti-mouse IgG) was also diluted in TBS-T and treated for 1 hour, followed by washing three times for 15 minutes each. Finally, the membrane was treated with Western HRP substrate (Merck Millipore, Burlington, USA), and images were taken using a ChemiDoc MP Imaging system (Bio-rad, CA, USA) to observe specific bands.

[0085] As a result, all 45 antigens showed high protein expression compared to wild-type RSV BF (#control 1, SEQ No. 1) and DC with Ds-Cav1 mutation introduced (#control 3, SEQ No. 3) (see Fig. 2).

[0086] Meanwhile, the influenza M1 protein is located on the cytoplasmic side of the plasma membrane after translation and exhibits the characteristic of being released through a budding process that surrounds the plasma membrane when it accumulates above a certain level. For the RSV Pre F protein to be effectively arranged on the surface of the VLP formed by the M1 protein, it is necessary to penetrate the plasma membrane and align at an appropriate membrane location after expression. The novel RSV Pre F protein produced in this invention contains the transmembrane domain of the influenza hemagglutinin protein (HA), allowing it to move to the plasma membrane of Sf9 cells after protein translation. Accordingly, immunofluorescence staining was performed to confirm the intracellular expression location of the RSV Pre F protein. Recombinant baculovirus expressing RSV Pre F was infected into insect cells (Sf9) and collected 72 hours later. The cells were fixed on a slide glass, and an RSV F-specific monoclonal antibody (2F7) specific to the F protein and fluorescent Goat Anti-mouse IgG H&L (Alexa Fluorescent) were applied. ᆴ After fluorescently staining the F protein on the cell surface using 488), the location of the RSV Pre F protein was confirmed using a confocal laser scanning microscope (Zeiss, Oberkochen, Germany) (see Fig. 3). As a result, no fluorescence was detected in the negative control, in which the F protein was not expressed, and the N-terminal region of the Pre F protein was exposed outside the surface of the Sf9 cell. It was confirmed that the Pre F protein maintained a membrane protein shape suitable for arrangement on the VLP surface by observing the pattern of concentrated location of the Pre F protein.

[0087]

[0088] Example 4: Primary selection of RSV B Pre-F antigen

[0089] To select superior candidates from among 45 structurally stabilized RSV B Pre-F antigen candidates, flow cytometry was performed on Pre-F proteins expressed on the cell surface. For the selection of RSV Pre-F antigen candidates, Nirsevimab (MedChemExpress, NJ, USA), a monoclonal antibody specific to site Ø of the Pre-F protein, and Motavizumab (MedchemExpress, NJ, USA), a monoclonal antibody specific to site II capable of binding to both Pre-F and Post-F proteins, were used. Nirsevimab is a site Ø-specific antibody that induces the production of neutralizing antibodies essential for RSV prevention and binds only to the Pre-F form of the protein, whereas Motavizumab binds to all F proteins regardless of form, allowing for the determination of total expression levels. 4 × 10⁶ cells were placed in a 25-tablet flask. 6 Sf9 cells dispensed at cells / mL were each inoculated with 45 types of recombinant baculovirus at an MOI of 0.1, and after collecting the cells on the 3rd day and counting them, 2.5 × 10 5The cells were dispensed into ep tubes to a cell / mL ratio and washed with DPBS. After removing DPBS, antibodies diluted to 1 µg / ml in eBioscience Flow Cytometry staining buffer (Invitrogen, USA) were treated at 4°C for 1 hour and washed once with DPBS. Subsequently, fluorescently labeled secondary antibodies (Alexa fluor 488) diluted to 0.2 µg / ml were stained at 4°C for 1 hour, followed by a single wash with DPBS, after which flow cytometry analysis was performed. Mean Fluorescence Intensity (MFI) was obtained from flow cytometry results using two types of antibodies for a total of 45 candidates. The highest MFI value within each group was fixed as the maximum value of 1, and Normalized MFI values ​​were calculated by converting the values ​​of the remaining candidates relative to it. Subsequently, proteins maintaining the Pre-F form were selected first, and to prevent candidates in the Post-F form from being selected based on simple expression levels, weights were assigned to the MFI values ​​obtained by each antibody, and the top two candidates from each group were initially selected. Nirsevimab was assigned a weight of 70% as it is the most important antibody for detecting the Pre-F form protein, as it selectively binds only to Site Ø (Site Zero) of the RSV F protein; Motavizumab was assigned a weight of 30% as it binds to Site II, recognizes both Pre-Fusion and Post-Fusion forms, and is an antibody for confirming the total expression level of the F protein.

[0090] ※ Score = (0.7 × Nirsevimab norm.MFI + 0.3 × Motavizumab norm.MFI)

[0091]

[0092] As a result, MFI values ​​were obtained for two types of antibodies against 45 antigen candidates (Group #1: 15 types with increased α-helix hydrogen bonds, Group #2: 3 types with increased hydrophobic interactions, Group #3: 7 types with increased Di-tyrosine cross-link formation, Group #4: 15 types with increased interprotomer disulfide bonds, Group #5: 5 types with enhanced protein stability) to stabilize the Pre F form, and within-group comparisons were performed (see Figs. 4 to 8).

[0093] Weights were applied to the MFI values ​​of all candidates to convert them into scores, and the top two candidates from each group were selected (see Table 3).

[0094]

[0095] Group#1#2#3#4#511-62-23-74-25-121-92-13-44-15-4

[0096] ※ Weighted values ​​are converted scores for within-group selection and cannot be used for inter-group comparison.

[0097]

[0098] Example 5. Re-verification of RSV B Pre-F antigen selection

[0099] Based on the results of the first selection, the reproducibility and significance of the candidate selection results were confirmed through repeated experiments using the same two types of antibodies on the top two antigen candidates selected from each group. Insect cells (Sf) infected with recombinant baculovirus were treated with Nirsevimab and Motavizumab antibodies in the same manner as in Example 4 and above, and three analyses were performed to confirm the reproducibility with the first selection results and to confirm the significance of the analysis results, thereby re-verifying the first selection results (see Fig. 9).

[0100]

[0101] Example 6. Final selection of RSV B Pre-F antigen

[0102] The purpose of the present invention to produce and select Pre-F antigen candidates based on the sequences of domestically prevalent strains is to develop a safe vaccine against Enhanced Respiratory Disease (ERD). Accordingly, to produce a vaccine candidate that induces a safe immune response using an antigen with confirmed stability in the Pre-F form rather than an antigen with excellent expression levels of simple F protein, the final selection is made of a candidate with a high content of the Pre-F form among the F proteins expressed on the surface of insect cells (Sf9). Specifically, by comparing the relative content of the Pre-F form among the total F protein expressions, a candidate with a higher Pre-F content was determined to be superior in terms of vaccine efficacy; furthermore, Nirsevimab MFI and Motavizumab MFI values ​​were calculated, and the candidate with the highest value was finally selected.

[0103] It was confirmed that the content of the Pre-F form among the total F proteins expressed for each antigen in Group #1 was significantly higher for antigen 1-9 than for 1-6 (see Fig. 10A). In flow cytometry, 82.1% of antigen 1-9 tested positive for motavizumab antibody and 72.8% for Nirsevimab antibody (see Figs. 10B and 10D), while 79.8% of antigen 1-6 tested positive for motavizumab antibody and 68.5% for Nirsevimab antibody (see Figs. 10C and 10E). Accordingly, antigen 1-9 showed a high Pre-F content and was predicted to have excellent efficacy in inducing neutralizing antibodies, so it was selected as the final candidate for Group #1.

[0104] It was confirmed that the content of the Pre-F form among the total F proteins expressed for each antigen in Group 2 was significantly higher for Antigen 2-2 than for 2-1 (see Fig. 11A). In flow cytometry, 84.8% of Antigen 2-2 tested positive for motavizumab antibody and 82.2% for Nirsevimab antibody (see Figs. 11B and 11D), while 84.1% of Antigen 2-1 tested positive for motavizumab antibody and 80.4% for Nirsevimab antibody (see Figs. 11C and 11E). Accordingly, Antigen 2-2 showed a high Pre-F content and was predicted to have excellent efficacy in inducing neutralizing antibodies, so it was selected as the final candidate for Group 2.

[0105] It was confirmed that the content of the Pre-F form among the total F proteins expressed for each antigen in Group #3 was higher for antigen 3-7 than for antigen 3-4 (see Fig. 12A). In flow cytometry, 82.9% of antigen 3-7 tested positive for motavizumab antibody and 79.3% for Nirsevimab antibody (see Figs. 12B and 12D), while 77.4% of antigen 3-4 tested positive for motavizumab antibody and 76.3% for Nirsevimab antibody (see Figs. 12C and 12E). Accordingly, antigen 3-7 showed a high Pre-F content and was predicted to have excellent efficacy in inducing neutralizing antibodies, so it was selected as the final candidate for Group #3.

[0106] It was confirmed that the content of the Pre-F form among the total F proteins expressed for each antigen in Group #4 was significantly higher for antigen 4-2 than for 4-1 (see Fig. 13A). In flow cytometry, 70.2% of antigen 4-2 tested positive for motavizumab antibody and 75.6% for Nirsevimab antibody (see Figs. 13B and 13D), while 70.4% of antigen 4-1 tested positive for motavizumab antibody and 75.2% for Nirsevimab antibody (see Figs. 13C and 13E). Accordingly, antigen 4-2 showed a high Pre-F content and was predicted to have excellent efficacy in inducing neutralizing antibodies, so it was selected as the final candidate for Group #4.

[0107] It was confirmed that the content of the Pre-F form among the total F proteins expressed for each antigen in Group 5 was significantly higher for Antigen 5-1 than for 5-4 (see Fig. 14A). In flow cytometry, 83.6% of Antigen 5-1 tested positive for motavizumab antibody and 86.0% for Nirsevimab antibody (see Figs. 14B and 14D), while 83.5% of Antigen 5-4 tested positive for motavizumab antibody and 80.7% for Nirsevimab antibody (see Figs. 14C and 14E). Accordingly, Antigen 5-1 showed a high Pre-F content and was predicted to have excellent efficacy in inducing neutralizing antibodies, so it was selected as the final candidate for Group 5.

[0108]

[0109] Example 7. Verification of the usefulness of the Pre-F selection antigen of RSV B

[0110] To verify the utility of the finally selected antigen against RSV B, a comparison was performed with the Ds-Cav1 variant applied to currently commercialized RSV vaccines. However, since commercial vaccines could not be secured as a control group, the Ds-Cav1 variant was introduced into the F protein sequence of domestically circulating RSV B (#control 3), and proteins were expressed in the same manner as the finally selected antigen to conduct a comparative evaluation. The evaluation was carried out using flow cytometry, the same method as for the final selection. As a result of comparing the relative content of the Pre-F form among the total F protein expressions, it was confirmed that among the selected antigens, 4-2, 3-7, and 2-2 had higher content of the Pre-F form compared to Ds-Cav1, and among them, antigen 4-2 was found to be the most superior (see Fig. 15).

[0111]

[0112] Example 8. Preparation of a Virus-Like Particle (VLP) Vaccine Candidate Containing RSV Pre F Protein Antigen

[0113] To produce virus-like particles containing the previously selected antigen, a recombinant baculovirus expressing the influenza M1 gene of SEQ ID NO. 51 was produced in the same manner as in Example 2. Subsequently, the RSV Pre F protein and the influenza M1 gene were simultaneously expressed in insect cells for 72 hours, and to obtain virus-like particles present in the culture supernatant, the cells were centrifuged at 3,000×g for 10 minutes to remove cell debris and the supernatant was collected. Then, the VLPs were precipitated by ultracentrifugation at approximately 100,000×g for 1 hour, and the precipitate was resuspended in PBS.

[0114]

[0115]

[0116]

[0117] Foregoing, specific parts of the present invention have been described in detail. It will be apparent to those skilled in the art that such specific descriptions are merely preferred embodiments and do not limit the scope of the invention. Accordingly, the actual scope of the invention is defined by the appended claims and their equivalents.

[0118]

[0119]

Claims

1. As a recombinant respiratory syncytial virus (RSV) F protein, Recombinant RSV F protein in which S155C, S290C, S190F, V207L, R106N, R108N, R135Q, R136Q, D486N, and K226Y amino acid substitutions are introduced into the wild-type RSV F protein.

2. In Paragraph 1, The above wild-type RSV F protein is a recombinant RSV F protein consisting of the amino acid sequence of SEQ ID NO.

1.

3. In Paragraph 1, The above recombinant RSV F protein is a recombinant RSV F protein composed of the amino acid sequence of SEQ ID NO.

5.

4. In Paragraph 1, The recombinant RSV F protein further comprises one or more amino acid substitutions selected from the group consisting of N228K, E232N, L203I, and S215P.

5. In Paragraph 4, The above recombinant RSV F protein is a recombinant RSV F protein composed of any one of the amino acid sequences of SEQ ID NOs 6 to 20.

6. In Paragraph 4, The above recombinant RSV F protein is a recombinant RSV F protein composed of the amino acid sequence of SEQ ID NO. 11 or SEQ ID NO.

14.

7. In Paragraph 1, The above-mentioned recombinant RSV F protein is a recombinant RSV F protein that further comprises an amino acid substitution of N67I, N67F, or N67W.

8. In Paragraph 7, The above recombinant RSV F protein is a recombinant RSV F protein composed of any one of the amino acid sequences of SEQ ID NOs 21 to 23.

9. In Paragraph 7, The above recombinant RSV F protein is a recombinant RSV F protein composed of the amino acid sequence of SEQ ID NO. 21 or SEQ ID NO.

22.

10. In Paragraph 1, The recombinant RSV F protein further comprises one or more amino acid substitutions selected from the group consisting of N428Y, V185Y, and V220Y.

11. In Paragraph 10, The above recombinant RSV F protein is a recombinant RSV F protein composed of any one of the amino acid sequences of SEQ ID NOs 24 to 30.

12. In Paragraph 10, The above recombinant RSV F protein is a recombinant RSV F protein composed of the amino acid sequence of SEQ ID NO. 27 or SEQ ID NO.

30.

13. In Paragraph 1, The recombinant RSV F protein further comprises one or more amino acid substitutions selected from the group consisting of Q98C, Q361C, N183C, and A149C.

14. In Paragraph 13, The above recombinant RSV F protein is a recombinant RSV F protein composed of any one of the amino acid sequences of SEQ ID NOs 31 to 45.

15. In Paragraph 13, The above recombinant RSV F protein is a recombinant RSV F protein composed of the amino acid sequence of SEQ ID NO. 31 or SEQ ID NO.

32.

16. In Paragraph 1, The recombinant RSV F protein described above is a recombinant RSV F protein further comprising an amino acid substitution of I79M, P101S, P101Q, I152V, or I152M.

17. In Paragraph 16, The above recombinant RSV F protein is a recombinant RSV F protein composed of any one of the amino acid sequences of SEQ ID NOs 46 to 50.

18. In Paragraph 16, The above recombinant RSV F protein is a recombinant RSV F protein composed of the amino acid sequence of SEQ ID NO. 46 or SEQ ID NO.

49.

19. A polynucleotide encoding a recombinant RSV F protein according to any one of claims 1 to 18.

20. An expression vector comprising the polynucleotide of claim 19.

21. Transformed host cell into which the expression vector of paragraph 20 has been introduced.

22. A virus-like particle comprising a recombinant RSV F protein according to any one of claims 1 to 18.

23. A virus-like particle according to paragraph 22, wherein the virus-like particle further comprises an influenza M1 protein.

24. A vaccine composition for preventing or treating RSV infection, comprising a recombinant RSV F protein according to any one of claims 1 to 18 as an active ingredient.

25. A vaccine composition for the prevention or treatment of RSV infection comprising the polynucleotide of claim 19 as an active ingredient.

26. A vaccine composition for the prevention or treatment of RSV infection comprising the expression vector of claim 20 as an active ingredient.

27. A vaccine composition for preventing or treating RSV infection, comprising the host cells of claim 21 as an active ingredient.

28. A vaccine composition for the prevention or treatment of RSV infection comprising the virus-like particle of claim 22 as an active ingredient.